SCHEMBL1940261

SCHEMBL1940261

Cc1cc(C)cc(NC(=O)c2cccnc2SCc2ccnc(N3C(=O)COCC3=O)c2)c1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDR P35968 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.41
TP53 P04637 1/20 0.41
ATM Q13315 1/20 0.38
PKM P14618 3/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
KMT2A Q03164 2/20 0.37
TAS2R8 Q9NYW2 1/20 0.37
MEN1 O00255 1/20 0.37
CYP2C9 P11712 2/20 0.37
ALDH1A1 P00352 1/20 0.37
KDM4E B2RXH2 2/20 0.37
HTT P42858 2/20 0.37
LMNA P02545 3/20 0.36
MAPT P10636 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1941886 0.92 KDR (0.48) KDRSMN1; SMN2TP53ATMPKM
SCHEMBL1940883 0.85 KDR (0.47) KDRSMN1; SMN2TP53ALDH1A1KDM4E
SCHEMBL1940260 0.84 KDR (0.49) KDRSMN1; SMN2TP53ATMPKM
SCHEMBL1941128 0.82 KDR (0.48) KDRSMN1; SMN2TP53PKML3MBTL1
SCHEMBL1942005 0.82 KDR (0.47) KDRSMN1; SMN2TP53ATMPKM
SCHEMBL4017154 0.81 KDR (0.56) KDRSMN1; SMN2TP53PKML3MBTL1
SCHEMBL1943078 0.81 KDR (0.46) KDRSMN1; SMN2TP53ATMPKM
SCHEMBL1941819 0.81 KDR (0.46) KDRSMN1; SMN2TP53L3MBTL1CYP2C9
Hydrochloric Acid SCHEMBL1942594 0.81 KDR (0.46) KDRSMN1; SMN2TP53ATMPKM
SCHEMBL4023317 0.80 KDR (0.53) KDRSMN1; SMN2TP53PKML3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1717229-B1 NOVEL CYCLIC COMPOUND HAVING 4-PYRIDYLALKYLTHIO GROUP HAVING (UN)SUBSTITUTED AMINO INTRODUCED THEREIN SANTEN PHARMACEUTICAL CO LTD (JP) 2011-06-15 EP disclosed
US-7544703-B2 Cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-06-09 US disclosed
US-20070149574-A1 Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein SANTEN PHARMACEUTICAL CO., LTD. (JP) 2007-06-28 US disclosed
EP-1717229-A1 NOVEL CYCLIC COMPOUND HAVING 4-PYRIDYLALKYLTHIO GROUP HAVING (UN)SUBSTITUTED AMINO INTRODUCED THEREIN SANTEN PHARMACEUTICAL CO., LTD. (JP) 2006-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149574-A1 Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein FLT4, FLT1, TIE1 KDR 12/4885SMN1; SMN2 4412/4885TP53 1624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.